Alphabet's DeepMind forms AI drug discovery unit Isomorphic Labs

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-17T21:36:06.092Z • Permanent link

DeepMind, the artificial intelligence division of Alphabet Inc., has announced the formation of a new unit dedicated to AI-driven drug discovery. Isomorphic Labs is the brainchild of a team led by Dr. Katia Vogel, a renowned expert in the field of machine learning and computational biology. Vogel, who joined DeepMind in 2017, has been instrumental in developing the company's AI-powered drug discovery platform, which has already shown promising results in accelerating the discovery of new treatments for complex diseases.

The new unit is based in London, UK, and will operate independently of DeepMind's other research divisions. Isomorphic Labs will focus on developing and applying advanced AI algorithms to identify novel molecular interactions and predict the efficacy of potential drugs. The team will work closely with researchers from academia and industry to translate these findings into tangible therapeutic solutions. According to sources, the unit has already secured funding from various venture capital firms and is expected to make its first investments in the coming months.

The launch of Isomorphic Labs marks a significant milestone in DeepMind's quest to apply AI to the complex task of drug discovery. The company has been at the forefront of this effort for several years, and its progress has been marked by several high-profile collaborations with leading pharmaceutical companies. The formation of Isomorphic Labs is seen as a natural next step, allowing DeepMind to expand its capabilities and reach a wider range of applications.

The emergence of Isomorphic Labs has significant implications for the pharmaceutical industry, which has long struggled to discover new treatments for complex diseases. Traditional drug discovery methods are often slow, expensive, and unpredictable, resulting in significant delays and costs. In contrast, AI-driven approaches like those being developed by Isomorphic Labs have the potential to revolutionize the field, enabling researchers to identify promising leads and accelerate the development of new therapies.

The impact of Isomorphic Labs will be felt across the industry, with major pharmaceutical companies such as Pfizer, Merck, and GlaxoSmithKline likely to take notice. These companies have already begun to invest heavily in AI research and development, recognizing the potential for these technologies to drive innovation and improve patient outcomes. The launch of Isomorphic Labs is seen as a major boost to these efforts, providing a new source of talent, expertise, and resources to support the development of AI-powered therapies.

The formation of Isomorphic Labs is part of a broader trend in the pharmaceutical industry towards increased adoption of AI and machine learning technologies. This shift is driven by the need to address the complex challenges of modern medicine, including the need to identify new targets for therapy, optimize treatment regimens, and improve patient outcomes. Other companies, such as IBM, Microsoft, and Novartis, have also established AI research divisions in recent years, and the field is expected to continue to grow and evolve in the coming years.